agree probably scheduled selling, also this might be the end of the period when no insiders could sell to avoid any insider trading, same as ban on selling and buying around quarterly earnings announcements
I recall a big deal was made when Nader sold some shares at aroiund $16 prior to the approval of Gattex. I agree insider sales are not a good thing, however, had there been no delay, these sales (if scheduled) would have been after approval. Wholesale selling by insiders liquidating their positions would be a RED flag. These small sales, not so much....thoughts?
tail, can we get your EXPERT analysis please, please admit we havent lost a beat since the delay.
But when 3 insiders sell almost $1 million shares in just two days on 27th and 28th at between $4.10-$4.55 tells you they were smart to get out as soon as possible as HUGE drop so far in just 2-3 days.
Sloth's number 1 rule to live by: Anything "The Street" publishes is just an attempt to leverage the stock price.
Yes a large number of shares were sold by the Exec Vice Prez, but that could be (and probably is) just to pay for something. A car. A house. Pizza.
No sweat, no worries. NPSP should test 29 by close.
according to you, we where supposed to be dropping every day, since the delay was announced. oh, let me guess, there was institutional selling this morning, followed by retail buys ? lol - go away
Johnny, You are good! Keep up the helpful cotribuitions to this board.
Wedbush Sets Expectations On NPS Pharmaceuticals Heading Into Q314 Earnings Release
October 30, 2014 9:47 AM EDT by Editor Ben Mahaney in Analyst Insights, Healthcare
In a research report issued Thursday, Wedbush analyst David Nierengarten maintained an Outperform rating on NPS Pharmaceuticals (NASDAQ:NPSP) with a price target of $42, as the company will report Q3 earnings in the first half of November.
Nierengarten said, “NPSP is expected to report Q3 earnings in the first half of November, and we expect earnings and sales in line with the Street. We are forecasting EPS of $0.01 and $58.2M in revenues, including $28.1M in Gattex sales, compared to consensus of $0.01 EPS and $59.5M in revenues.” The analyst added, “Although we expect the earnings call to be dominated by talk of Natpara, specifically surrounding FDA feedback and the required REMS submission, we believe recent investor focus on Natpara has overshadowed the strong growth in the Gattex franchise.”
The analyst concluded, “NPSP remains one of the best values among publically-traded rare disease companies. We recommend investors take advantage of recent weakness and accumulate NPSP shares prior to the extended (and in our view, de-risked) approval for Natpara on Jan 24, 2015.”
OMER - new drug one of a kind to be used in catarac surgery
TGTX - cancer drugs to be used in combo and alone,
please do your own dd, i dont have time to write more of the positives.